Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.54 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 3.21 - 18.33 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 11.54 | USD |
Iovance Biotherapeutics (IOVA) Options Flow Summary
Iovance Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.22B | 279.31M | - | 1.19M | -444.04M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iovance Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.60 | 12.14 | 11.01 | 11.54 | 3,560,872 | -0.06 | -0.52% |
1 Month | 14.71 | 14.77 | 11.01 | 12.59 | 4,173,837 | -3.17 | -21.55% |
3 Months | 7.802 | 18.33 | 7.60 | 13.92 | 9,194,761 | 3.74 | 47.91% |
6 Months | 3.66 | 18.33 | 3.47 | 10.48 | 8,281,788 | 7.88 | 215.30% |
1 Year | 5.53 | 18.33 | 3.21 | 8.81 | 7,152,440 | 6.01 | 108.68% |
3 Years | 31.73 | 33.55 | 3.21 | 10.68 | 4,454,953 | -20.19 | -63.63% |
5 Years | 11.02 | 54.2081 | 3.21 | 14.32 | 3,300,334 | 0.52 | 4.72% |
Iovance Biotherapeutics Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. |